These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28351543)

  • 1. Corrigendum to "Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies" [Schizophr. Res. 174 (2016) 82-92].
    Correll CU; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Kane JM
    Schizophr Res; 2017 Dec; 190():191-194. PubMed ID: 28351543
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies.
    Correll CU; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Kane JM
    Schizophr Res; 2016 Jul; 174(1-3):82-92. PubMed ID: 27157799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Correll CU; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    Am J Psychiatry; 2015 Sep; 172(9):870-80. PubMed ID: 25882325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia.
    Kane JM; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    Schizophr Res; 2015 May; 164(1-3):127-35. PubMed ID: 25682550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum to "Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial" [Schizophr. Res. 176 (2016) 264-271].
    Durgam S; Earley W; Li R; Li D; Lu K; Laszlovszky I; Wolfgang Fleischhacker W; Nasrallah HA
    Schizophr Res; 2018 Feb; 192():493. PubMed ID: 28427929
    [No Abstract]   [Full Text] [Related]  

  • 6. Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies.
    Marder SR; Hakala MJ; Josiassen MK; Zhang P; Ouyang J; Weiller E; Weiss C; Hobart M
    Acta Neuropsychiatr; 2017 Oct; 29(5):278-290. PubMed ID: 27846922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
    Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
    McEvoy J; Citrome L
    Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
    Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
    J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
    Citrome L
    Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
    Kane JM; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Correll CU
    Schizophr Res; 2016 Jul; 174(1-3):93-98. PubMed ID: 27188270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brexpiprazole: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2016 Apr; 30(4):335-42. PubMed ID: 27023789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
    Citrome L; Ota A; Nagamizu K; Perry P; Weiller E; Baker RA
    Int Clin Psychopharmacol; 2016 Jul; 31(4):192-201. PubMed ID: 26963842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.
    Tandon R; Cucchiaro J; Phillips D; Hernandez D; Mao Y; Pikalov A; Loebel A
    J Psychopharmacol; 2016 Jan; 30(1):69-77. PubMed ID: 26645209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum to "Long-term hospitalizations for schizophrenia in the Czech Republic 1998-2012" (Schizophr. Res. vol. 175, issues 1-3, August 2016, pages 180-185).
    PetrWinkler ; Mladá K; Krupchanka D; Agius M; Ray MK; Höschl C
    Schizophr Res; 2016 Oct; 176(2-3):581. PubMed ID: 27476650
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Phenotype continuum between autism and schizophrenia: Evidence from the Movie for the Assessment of the social cognition (MASC)" [Schizophr. Res. 185 (2017) 161-166].
    Martinez G; Alexandre C; Mam-Lam-Fook C; Bendjemaa N; Gaillard R; Garel P; Dziobek I; Amado I; Krebs MO
    Schizophr Res; 2018 Mar; 193():489. PubMed ID: 29550055
    [No Abstract]   [Full Text] [Related]  

  • 18. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.
    Durgam S; Cutler AJ; Lu K; Migliore R; Ruth A; Laszlovszky I; Németh G; Meltzer HY
    J Clin Psychiatry; 2015 Dec; 76(12):e1574-82. PubMed ID: 26717533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum to "Increased diffusivity in gray matter in recent onset schizophrenia is associated with clinical symptoms and social cognition" [Schizophr. Res. 176 (2-3) (Oct 2016) 144-150].
    Lee JS; Kim CY; Joo YH; Newell D; Bouix S; Shenton ME; Kubicki M
    Schizophr Res; 2017 Mar; 181():137. PubMed ID: 27890401
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "resilience in schizophrenia: A comparative study between a remote island and an urban area in Japan" [Schizophr. Res. Volume 171, Issues 1-3, March 2016, Pages 92-96].
    Yoshida K; Suzuki T; Imasaka Y; Kubo KI; Mizuno Y; Saruta J; Tsukinoki K; Mimura M; Uchida H
    Schizophr Res; 2016 Oct; 176(2-3):580. PubMed ID: 27539074
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.